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ABSTRACT 
PATIENT MOTIVATIONAL LANGUAGE AS A PREDICTOR OF SYMPTOM 
CHANGE, HAZARD OF CLINICALLY SIGNIFICANT RESPONSE, AND TIME TO 
RESPONSE IN PSYCHOTHERAPY FOR GENERALIZED ANXIETY DISORDER  
FEBRUARY 2019 
BRIEN J. GOODWIN, B.A., UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Michael J. Constantino 
Change-talk (CT), or self-arguments for change, has been associated with favorable 
patient outcomes, while counter change-talk (CCT), or self-arguments against change, 
has been associated with poorer outcomes. Most studies on change language have 
focused on the prediction of distal posttreatment outcomes, while the prediction of more 
proximal outcomes has remained largely untested. Addressing this gap, we examined 
early treatment CT and CCT as predictors of worry change trajectories, “hazard” of 
clinically significant response, and time to response (i.e., outcome efficiency) in CBT and 
CBT integrated with MI (MI-CBT) for generalized anxiety disorder (GAD). We also 
explored whether treatment type moderated these associations. Data derived from a 
randomized controlled trial comparing CBT (n = 43) and MI-CBT (n = 42) for GAD. 
Independent observers reliably coded CT/CCT during session 1. Patients rated their 
worry after every session. Multilevel modeling revealed that, across both treatments, 
more CT associated with lower midtreatment worry level (p = .03), whereas more CCT 
associated with a slower rate of worry reduction at midtreatment (p = .04). However, 
treatment moderated the associations between CT and both midtreatment worry level (p = 
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.004) and rate of change (p = .03). In CBT, patients with higher vs. lower CT had less 
worry and a faster rate of worry reduction; in MI-CBT, CT was unrelated to midtreatment 
worry level and the rate of worry change. Treatment did not moderate the CCT-worry 
relations. Survival analyses revealed that, across both treatments, more CT associated 
with a greater hazard of response (p = .004) and approached a faster time to response (p = 
.05), and more CCT associated with a lower hazard of response (p = .002) and 
approached a slower time to response (p = .06). Patient motivational language predicts 
proximal outcomes, and may be useful in differential treatment selection. 
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CHAPTER 1 
INTRODUCTION 
 
Generalized anxiety disorder (GAD) is a commonly-occurring condition, with a 
12-month prevalence of 2.9% for adults (American Psychiatric Association, 2013). GAD 
is also highly comorbid with other psychological problems; in a large stratified sample (N 
= 8,098) across 172 countries, 90.4% of participants who met criteria for GAD also 
reported a lifetime history of another mental disorder (Wittchen, Zhao, Kessler, & Eaton, 
1994). Moreover, GAD is debilitating, with sufferers experiencing substantial impairment 
across the domains of education, career development, economic productivity, and social 
relationships (Mendlowicz & Stein, 2002; Wittchen, Carter, Pfister, Montgomery, & 
Kessler, 2000). Thus, the need for effective GAD treatments is well-established. 
The most prominent psychosocial treatment for this condition is cognitive-
behavioral therapy (CBT), which has proven somewhat effective in reducing the hallmark 
GAD symptom of pathological worry (Covin, Ouimet, Seeds, & Dozois, 2008). Yet, 
overall, CBT for GAD response rates remain somewhat sobering. Across two meta-
analyses, less than 50% of patients achieved clinically significant improvement by 
treatment termination (Hunot, Churchill, Teixeira & Silve de Lima, 2007; Westen & 
Morrison, 2001). Thus, there remains clear room for refinement, even for the current 
“gold-standard” intervention. 
Specific to CBT for GAD, some have posited that one patient-level characteristic 
that may inhibit treatment response is low motivation for change (Arkowitz & Westra, 
2004; Engle & Arkowitz, 2006; Westra, 2004, 2012). This low motivation may, in part, 
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be related to the nature of the pathology, as people with GAD typically possess some 
ambivalence about relinquishing their worry (Borkovec & Roemer, 1995). On the one 
hand, these individuals may be driven to reduce the disability that results from excessive 
and uncontrollable worry; on the other hand, such worry can be seen as an adaptive 
mechanism of readiness and control (Borkovec, 1994; Newman, Llera, Erickson, 
Przeworski, & Castonguay, 2013). Thus, the reliable assessment of patient motivation 
may provide important information for effectively treating persons with GAD. 
 However, measuring motivation has proven challenging. Self-report measures 
have been historically unreliable predictors of clinical outcomes in CBT for anxiety 
disorders (Kampman, Keijsers, Hoogduin, & Hendriks, 2008; Poulin, Button, Westra, 
Constantino, & Antony, 2018; Vogel, Hansen, Stiles, & Gotestam, 2006). For example, 
in one study of CBT for GAD, only one of two self-report measures related to both 
proximal and distal outcomes, whereas an observational measure of patients’ in-session 
resistance (one potential manifestation of low, or at least conflicted, change motivation) 
consistently predicted outcomes in the expected direction (Westra, 2011). Moreover, 
when the self-report measures of motivation and the observer-based measure of in-
session resistance were included together in a simultaneous regression, only observer-
coded resistance predicted posttreatment worry. Westra posited that self-report measures 
of motivation may be more susceptible to social desirability bias than observer measures 
of related constructs; that is, although patients may be reticent to explicitly report low 
motivation to change, such low motivation may be reliably revealed through observation 
of in-session processes of resistance that suggest low change drive. 
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 In light of these comparative data sources, it seems that relying on explicit self-
report of motivation may be limiting. Moreover, in-session resistance, although certainly 
a useful construct to assess, may reflect a consequence of low motivation, as opposed to 
the low motivation construct itself. Fortunately, there is a promising way to combine an 
explicit focus on motivation proper with objective observations. This method relies on 
coding patient language content that implicitly reflects differing levels of motivation 
(Glynn & Moyers, 2009). Rooted in self-perception theory (Bem, 1967) and cognitive 
dissonance theory (Festinger, 1962), change-talk (CT) represents language in favor of 
adaptive behavior change, while counter change-talk (CCT) represents language in favor 
of maintaining the problem behavior (Miller & Rollnick, 2002). 
Studies to date have supported the predictive validity of these two types of 
motivational language across various treatments for various disorders. For example, in a 
meta-analysis of studies targeting behavior change with motivational interviewing (MI), 
motivational enhancement therapy (MET), and brief motivational interventions, patient 
CCT was negatively associated with adaptive outcomes (Magill et al., 2014). In another 
study focused on MET for problem drinking, patient CT and CCT were shown to predict 
positive and negative outcomes, respectively (Moyers et al., 2007). With regard to GAD 
in particular, several studies focused on standard CBT for GAD have demonstrated that 
variants of patient CCT, but not CT, were positively correlated with higher posttreatment 
and/or follow up worry outcomes (Hunter, Button, & Westra, 2013; Lombardi, Button, & 
Westra, 2014; Sijercic, Button, Westra, & Hara, 2016). In another study of GAD, this 
time across patients receiving either CBT or CBT integrated with MI, variants of CCT 
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again correlated positively with higher posttreatment and follow up worry outcomes, 
whereas higher CT associated with lower worry at follow up only (Poulin et al., 2018). 
In the extant GAD research base examining associations between motivational 
language and treatment outcomes, CT and CCT have largely been assessed at baseline or 
early treatment, while the outcome variables have largely been assessed distally at 
posttreatment and/or follow up. To date, little attention has been paid to early treatment 
CT and CCT as predictors of more proximal outcomes, such as trajectories of 
dimensional symptom change over the course of active treatment, the “hazard” of 
obtaining a clinically significant response at some point during treatment, or the time it 
takes for patients to reach clinically significant response criteria. Furthermore, with the 
exception of the Poulin et al. (2018) study, research examining the CT/CCT-outcome 
relations has tended to do so within single-school treatments only (e.g., MI or CBT 
alone). Thus, it seems important to continue to examine these questions in newer 
generation therapies for GAD that have integrated into CBT strategies that address some 
theoretically important and previously neglected feature of the disorder in an effort to 
improve patient response (e.g., Dugas et al., 2010; Newman et al., 2011; Wells et al., 
2010). 
For example, in a recent trial, investigators tested the value of responsively 
integrating MI into CBT, as a means to increase patients’ intrinsic motivation and change 
agency (Westra, Constantino, & Antony, 2016). Although there were no differences 
between standard CBT and MI-CBT at posttreatment, patients in MI-CBT showed 
significantly greater worry reduction across a 12-month follow up than CBT alone 
patients. These findings not only support the added efficacy for the integrative treatment 
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adaptation, but they also support examining predictors of change, like motivational 
language, in both standard CBT and the newer generation integrative CBT. 
Finally, it also seems important to address whether treatment type (e.g., a single-
school approach vs. an integrative approach) might formally moderate the language-
outcome associations. As there is no research or theory to suggest that language-outcome 
associations should systematically vary based on treatment, several rival ideas can be 
examined. On the one hand, it could be that language has stronger effects on outcomes 
(negative or positive) when a therapist addresses low motivation in a directive manner, as 
is the case when CBT therapists treat low change drive as a problem or distorted 
cognition to be actively challenged and resolved. Alternatively, language may have 
stronger effects on outcomes when the therapist responds to low motivation in a non-
directive, patient-centered, and autonomy-preserving manner, as is the case in MI-CBT. 
If such systematic variability exists, in whatever direction, it can inform future theory 
generation and research on what therapy factors are most effective for which patients. 
Extending the extant literature and drawing on data from the aforementioned 
Westra et al. (2016) trial, the goals of the present study were to test CT and CCT as 
predictors of (a) change in worry across acute treatment, (b) hazard of clinically 
significant response, and (c) time to clinically significant response across both standard 
CBT and MI-CBT for GAD. Consistent with the literature, we predicted that CT would 
be associated with steeper acute phase symptom reduction and a faster time to response, 
whereas CCT would have the opposite effect on these outcomes. Our question of whether 
treatment type (CBT vs. MI-CBT) would moderate these language-outcome associations 
was novel and exploratory. 
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CHAPTER 2 
METHOD 
 
2.1 Participants 
Patients were 85 adults randomly assigned to receive 15 sessions (50 minutes 
each) of either MI-CBT (n = 42) or CBT (n = 43) at one of two sites in Toronto, Canada. 
To be included in the trial, patients had to meet Diagnostic and Statistical Manual of 
Mental Disorders versions IV, Text Revision (DSM-IV-TR; American Psychiatric 
Association, 2000) and 5 (DSM-5; American Psychiatric Association, 2013) criteria for 
principal GAD, and score above a high worry severity cutoff of ≥ 68 on the Penn State 
Worry Questionnaire (PSWQ; Meyer, Miller, Metzger & Borkovec, 1990; described 
below). To enhance generalizability, most comorbid diagnoses were allowable. Also, 
although unmedicated patients were required to remain unmedicated during the trial, 
being on antidepressant medication was allowable if the individual was using the same 
medication and dose for at least 3 months prior to study inclusion and agreed to remain 
on this dose throughout treatment. Exclusion criteria were concurrent psychotherapy, 
benzodiazepine use, psychotic spectrum disorders or bipolar disorder, major cognitive 
impairment, substance dependence within the past 6 months, and significant current 
suicidal ideation. 
Therapists were 21 female doctoral students in clinical psychology programs who 
self-selected to treat patients in either MI-CBT (n = 9) or CBT (n = 12). This nesting was 
designed to mitigate allegiance effects. The MI-CBT therapists’ caseloads ranged from 1 
to 13 cases (Mdn = 4), while CBT therapists’ caseloads ranged from 1 to 6 cases (Mdn = 
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4). Therapists were trained through a combination of workshops and readings, and they 
were only allowed to treat study cases after demonstrating competence with at least one 
practice case. During the trial, supervision was provided by an expert in each condition, 
and it consisted of weekly individual meetings and video review. 
 
2.2 Treatments 
2.2.1 CBT 
 For both conditions, therapists delivered CBT according to multiple evidence-
based protocols for treating GAD (Borkovec & Costello, 1993; Borkovec & Mathews, 
1988; Borkovec, Newman, Pincus, & Lytle, 2002). Targeting the core features of GAD, 
including uncontrollable worry, inhibited emotional processing secondary to worry, and 
chronic hyperarousal, this multi-component treatment included psychoeducation about 
worry/anxiety, exposure to worry and worry cues, applied relaxation, behavioral 
approach tasks, self-monitoring of thoughts, and challenging of distorted cognitions. 
Therapists managed patient resistance using techniques recommended in the CBT 
literature (e.g., functional analysis, collaborative goal setting, problem-solving; Beck, 
2005; Sanderson & Bruce, 2007; Tompkins, 2004). 
  
2.2.2 MI-CBT 
Therapists delivered the integrative treatment according to Westra’s (2012) guidelines for 
assimilating MI principles (Miller & Rollnick, 2002) into action-oriented treatments (like 
CBT) for anxiety. Applied to GAD, MI is a person-centered approach focused on helping 
patients resolve ambivalence about reducing their worry and addressing interpersonal 
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resistances that might stem from such ambivalence. MI-specific strategies include 
helping patients develop discrepancies between their current experiences and their most 
valued experiences (to promote self-arguments for moving toward their valued self) and 
purposefully “rolling with” patient resistance by empathically exploring both the positive 
and negative aspects of behavior change, while validating and normalizing ambivalence 
about changing.  
 Procedurally, patients first received up to 4 preparatory sessions of MI, followed 
by 11 CBT sessions with MI responsively integrated. Although the typical patient 
received all 4 of the “pure” MI sessions, for patients who were highly motivated for 
change-oriented interventions, the shift to CBT occurred 1 to 2 sessions earlier. In the 
subsequent CBT-based sessions, therapists continued to use MI “spirit” (collaboration, 
empathy, validation, evocation, and enhancing self-efficacy) as a foundational stance, and 
they explicitly shifted into primary MI strategies in response to markers of patient 
resistance. Once a resistance episode was deemed resolved, therapists shifted back into 
CBT with MI spirit. These marker-driven responsive shifts occurred as needed. Therapist 
adherence to their respective treatment protocol was observer-rated on a random subset of 
20% of sessions for each therapist in each condition. As expected, adherence to CBT was 
high across both conditions, with adherence measures discriminating between conditions 
on the key components of preparatory and responsively integrated MI (see Westra et al., 
2016, for details). 
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2.3 Measures 
 
2.3.1 Patient Motivational Language 
CT and CCT were observer-assessed according to an adapted (for CBT; Lombardi 
et al., 2014) version of the Motivational Interviewing Skills Code 1.1 (MISC 1.1; Glynn 
& Moyers, 2009). In this coding system, patient language across an entire session is first 
parsed into turns at talk, and then further deconstructed into utterances (i.e., complete and 
separate thoughts). Patient utterances are then coded as CT language in favor of changing 
the target behavior (e.g., “I want to stop worrying”) or CCT utterances in favor of 
sustaining the target behavior (e.g., “Worry makes me work extra hard”). All other non-
change-related patient utterances are left uncoded (Button, Westra, Hara, & Aviram, 
2015). The MISC has shown strong predictive validity in the treatment of problem 
drinking (Magill et al., 2014; Moyers et al., 2007) and GAD (e.g., Hunter et al., 2013; 
Lombardi et al., 2014; Poulin et al., 2018). 
The adapted MISC 1.1 coders were two upper-level undergraduate students in 
psychology and a clinical psychology master’s level graduate student. Coders were 
trained over four months, participating in two 3-hour training workshops and 
independently coding test material to determine proficiency. The study coders all 
achieved 85% observed agreement with criterion codes for the test materials. For the 
current study, 25% of the material was double coded to determine interrater reliability. 
Kappa coefficients for each pair of coders indicated good to excellent interrater reliability 
(average к = .86). 
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2.3.2 Worry 
The primary outcome variables for this study were derived from the PSWQ 
(Meyer et al., 1990), a widely-used self-report measure of trait worry. All 16 items are 
rated on a 5-point scale ranging from 1 to 5, with higher total scores reflecting more 
worry (range = 16 to 80). The PSWQ has sound psychometric properties (Brown, Antony, 
& Barlow, 1992; Meyer et al., 1990), and it demonstrated high internal consistency across 
the repeated measures in this study (average α = .93). 
 
2.4 Procedure 
 Participants responded to community advertisements posted in the greater 
Toronto area. After responding, potential participants were phone screened. If eligible, a 
trained graduate assessor administered the Structured Clinical Interview for DSM-IV-TR 
Axis I Disorders (SCID-I; First, Spitzer, Gibbon, & Williams, 1996) to consenting 
participants to determine diagnostic eligibility and assess other clinical features. Eligible 
patients were then randomized to treatment across the two sites. The randomization 
protocol was administered at a neutral third site by a co-investigator uninvolved in site 
procedures and therapist training, and blind to patient clinical features. The MISC 1.1 
was applied to motivational language uttered in the first session. The PSWQ was 
administered at baseline and after every session. The institutional review boards at the 
two data collection sites approved the trial, as well as subsequent secondary analyses of 
de-identified data. 
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2.5 Data Analysis 
First, to control for patient verbosity, ratios of CT and CCT frequencies to total 
session utterances were created, and these ratios were used as the predictor variables in 
all analytic models. Second, we calculated descriptive statistics for patient and therapist 
samples and all study variables, including their distributions and potential outliers. Third, 
we examined the intercorrelations among all study variables to determine if there were 
any problems of collinearity (e.g., between the baseline self-report variable of change 
motivation and session 1 motivational language). Finally, we addressed the primary 
research questions with three separate sets of analyses. 
To examine the relation between patient motivational language and change in 
worry during the acute treatment phase, we used multilevel modeling given its ability to 
account for dependencies in the data due to repeated measures.1 As our primary focus 
was on proximal rather than distal outcomes, time for the multilevel models was centered 
at midtreatment (session 7.5). Using the hierarchical linear modeling program (HLM7; 
Raudenbush, Bryk, & Congdon, 2011), we first fit two individual 2-level models (one for 
CT and one for CCT) to estimate within patient change in worry at level-1, and between 
patient differences in worry change at level-2. Visual inspection of the average rate of 
change in worry revealed a slight curvature. Thus, we first fit an unconditional linear 
model, and then an unconditional quadratic model to determine which model was a better 
fit to the data. Then, at level-2, we examined the effect of patient CT and CCT, 
                                                        
1 Although there is another source of dependency in these data (i.e., patients nested within therapists), 
we did not examine therapist effects on worry given that Westra et al. (2016) found that the therapist 
accounted for < 1% of the variability in patients’ posttreatment worry and during-treatment rates of change 
in worry. 
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respectively, on worry trajectories. To assess whether treatment condition moderated the 
association of each language variable and worry change, we added CT x treatment and 
CCT x treatment interaction terms to their respective model. Effect sizes were calculated 
by evaluating the additional percent variance explained with the addition of predictors (a 
pseudo r2 statistic). 
To examine the relation between patient motivational language and the hazard of 
clinically significant response (i.e., the instantaneous “risk” of achieving the response 
criteria at the next session), we used R: A language and environment for statistical 
computing (R Core Team, 2015) to estimate survival models. To determine statistically 
reliable and clinically significant response, we used Jacobson and Truax’s (1991) criteria, 
as Westra et al. (2016) did in the flagship outcome report for this trial; namely, to be 
considered a responder, patients had to pass an empirically derived cut point for reliable 
response (the Reliable Change Index; RCI) and clinically meaningful response (i.e., 
Cutoff C). Drawing on Gillis, Haaga, and Ford’s (1995) normative data, the PSWQ has a 
RCI of 9 and a Cutoff C of 58 (i.e., a score of  58 is closer to the normal than clinical 
range). Thus, we defined response as a decrease of 9 points on the PSWQ, with a score of 
 58. 
As the underlying hazard function for our variables was unknown, and the 
negative statistical repercussions of inaccurately specifying the hazard function are high, 
we used the semi-parametric Cox model (Cox, 1972) for our analyses. Though Cox 
models relax assumptions compared to fully parametric models (e.g., the Weibull 
proportional hazards model), there are two assumptions that need to be met to ensure 
reliability of Cox model estimates: non-informative censoring and proportional hazards. 
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To test the assumption that censoring was non-informative, we conducted a sensitivity 
analysis, first treating all censored cases as though they achieved clinically significant 
response at the time of censoring, and then treating all censored cases as though they 
achieved clinically significant response at the time point when the majority of patients 
achieved clinically significant response. 
 The assumption of proportional hazards is met when the ratio of hazards for any 
two patients is constant and is not time dependent. We tested this assumption through 
visual inspection of Schoenfeld residual plots, and the cox.zph function in R, which 
assessed the correlation of predictor variables with time. For any variable that violated 
this assumption, a time-varying covariate was created and included in the final model. In 
addition to the predictors of interest (CT and CCT), we also assessed whether treatment 
condition moderated the association of each language variable and hazard of response by 
adding CT x treatment and CCT x treatment interaction terms to our final model. Finally, 
to examine the relation between patient motivational language and time to clinically 
significant response, we used Kaplan Meier curves. 
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CHAPTER 3 
RESULTS 
 
3.1 Preliminary Analyses 
 The mean CT and CCT ratios were 0.18 (SD = 0.11) and 0.11 (SD = 0.07), 
respectively. These variables did not significantly differ between conditions – CT: t(82.5) 
= -1.28, p = .20; CCT: t(82.5) = 1.05, p = .30. CT was non-normally distributed, with 
skewness of 2.20 (SE = 0.26) and kurtosis of 8.15 (SE = .52). CCT was also non-
normally distributed, with skewness of 1.46 (SE = 0.26) and kurtosis of 3.30 (SE = .52). 
Thus, we performed square root transformations on both predictors. The transformed CT 
has a skewness of 0.96 (SE = 0.26) and kurtosis of 1.91 (SE = .52), and the transformed 
CCT has a skewness of 0.31 (SE = 0.26) and kurtosis of 0.67 (SE = .52). Inspection of Q-
Q and stem-and-leaf plots revealed two statistical outliers for our predictor variables 
(CCT, z = 4.206; CT, z = 5.206). However, there was no reason to believe that these 
extreme values were a function of data entry or measurement error. Thus, they were 
considered legitimate observations and included in our analyses. Intercorrelations 
between predictors were weak to moderate (rs range from -.130 to .319).  
Table 1 presents the sample descriptive statistics by treatment condition. Between 
treatments, patients did not differ on baseline PSWQ or any demographic variable other 
than gender; there were more women and less men in the CBT vs. MI-CBT condition, χ2 
(1) = 4.24, p = .04. The groups differed significantly on baseline motivation for change, 
as assessed by the Change Questionnaire (CQ; Miller & Johnson, 2008), which includes 
12 items rated on a scale from 0 to 10. Specifically, CBT patients reported significantly 
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higher motivation than MI-CBT patients, t(83) = -2.55, p = .013. Furthermore, between 
group differences in medication status approached significance, with more CBT patients 
reporting medication use than MI-CBT patients, χ2 (1) = 3.94, p = .05. For our first 
primary research question, given the two treatment sites and the fact that the treatment 
groups differed on baseline change motivation and antidepressant medication status, we 
residualized out the effects of site, motivation, and medication from the PSWQ variable, 
as was done in the flagship outcome analyses for this trial (Westra et al., 2016). Thus, our 
variable for the multilevel models presented below represents the variability in worry that 
is not accounted for by these three baseline variables. For our second primary research 
question, we included site, baseline self-report motivation, and medication status as 
covariates in our model. 
Returning to the trial characteristics, attrition during the active treatment phase 
included 23% (n = 10) of CBT patients and 10% (n = 4) of MI-CBT patients. This 
differential attrition rate approached significance, χ2 (1) = 2.91, p = .09. Regarding 
therapists, they did not significantly differ between groups on age (MI-CBT, M = 28.33 
years; CBT, M = 29.08 years), t(19) = -.482, p = .64, or clinical experience (MI-CBT, M 
= 451.53 hours; CBT, M = 190.21 hours), t(7.20) = 1.13, p = .293. 
 
3.2 Motivational Language and Worry Change 
 Results of the model comparison test indicated that the unconditional quadratic 
model (see Table 2, column 1) was a significantly better fit to the data than the 
unconditional linear model, χ2(4) = 85.32, p < 0.001. We therefore used this quadratic 
model for our HLM analyses. To examine the CT-worry association, we added the 
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session 1 CT ratio to the quadratic model as a predictor at level-2 (see Table 2, column 
2). Higher CT was associated with lower worry at midtreatment (γ02 = -22.10, p = .03), 
accounting for 5% of the unexplained variance. Additionally, higher CT was marginally 
associated with greater worry reduction at midtreatment (γ12 = -2.32, p = .06), accounting 
for 4% of the unexplained variance. CT was unrelated to the rate of 
acceleration/deceleration in worry change across treatment. As per Table 2, column 3, the 
CT x treatment interaction term significantly predicted worry at midtreatment (γ03 = 
47.33, p = .03) and the rate of change in worry at midtreatment (γ13 = 5.47, p = .03); 
namely, in CBT, more session 1 CT was associated with a lower level of worry and a 
greater decrease in worry at midtreatment, whereas in MI-CBT, CT was unrelated to 
worry level and worry change at midtreatment. This moderating effect is graphically 
depicted in Figure 1. Finally, the CT x treatment interaction term was unrelated to the 
rate of acceleration/deceleration in worry change across treatment. 
To examine the CCT-worry association, we added the session 1 CCT ratio to the 
quadratic model as a predictor at level-2 (see Table 3, column 2). Higher CCT was 
associated with less worry reduction at midtreatment (γ12 = 2.88, p = .04), accounting for 
2% of the unexplained variance. CCT was unrelated to worry level at midtreatment and 
the rate of acceleration/deceleration in worry change across treatment. As per Table 3, 
column 3, the CCT x treatment interaction term was unrelated to worry level at 
midtreatment, the rate of change in worry at midtreatment, or the rate of 
acceleration/deceleration in worry change across treatment. 
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3.3 Motivational Language and Hazard of Clinically Significant Response 
 To examine the relation between patient motivational language and the hazard of 
clinically significant response, we conducted a Cox proportional hazards model, with the 
ratio of session 1 CT, the ratio of session 1 CCT, treatment group, a CT x treatment 
interaction term, and a CCT x treatment interaction term as predictors. (As noted, site, 
baseline self-report motivation, and medication status were included as covariates.) We 
first conducted a sensitivity analysis to test the assumption of non-informative censoring 
with the ratio of session 1 CT, the ratio of session 1 CCT, and treatment group. In our 
first model (see Table 4), all randomly censored cases were treated as though they 
experienced clinically significant response immediately after being censored (n = 85, 
number of events = 85). In our second model (see Table 5), all randomly censored cases 
were treated as though censoring occurred at the time-point when the majority of patients 
experienced clinically significant response (n = 85, number of events = 58). Comparison 
of the results of these two models indicated partially informative censoring, with 
variation between models particularly apparent in the differences in the coefficient for 
treatment group, β = -.04, p = .079; β = -.07, p = .79. However, in both of these extreme 
models, coefficients and p-values for our primary predictors of interest (CT and CCT) 
changed little, and we have no reason to believe that one of these extreme models is more 
accurate that our original model. 
Next, visual inspection of Schoenfeld residual plots did not indicate that the 
hazard of predictors varied with time. However, the cox.zph function in R, which 
correlates corresponding scaled Schoenfeld residuals with time, indicated that the 
proportional hazards assumption had been violated. In particular, session 1 CCT was 
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significantly correlated with time (p = 0.021). All other predictors, and the global test of 
the model, were not significantly correlated with time. To correct for the violation of 
proportional hazards, a CCT x time interaction term was added to our model. Our final 
Cox model with predictors, covariates, and interaction terms can be seen in Table 6. 
Results indicated that session 1 CT was a significant predictor in this model (HR = 1.04, 
p = 0.004), such that for every 1 unit increase in session 1 CT, there was 4.12% increase 
in the hazard of clinically significant response. Session 1 CCT was also a significant 
predictor (HR = 0.87, p = 0.002), such that for every 1 unit increase in session 1 CCT, 
there was a 7.44% decrease in the hazard of clinically significant response. Treatment 
group was also a significant predictor (HR = 0.58, p = 0.05), indicating that the hazard of 
clinically significant response for the CBT-only group was 72% that of the MI-CBT 
group. 
 
3.4 Motivational Language and Time to Clinically Significant Response 
To estimate the survival function for clinically significant response at differing 
levels of session 1 CT and CCT we used the Kaplan Meir estimator, with corresponding 
plots of the survival function. Patients in the upper 75th percentile of session 1 CT had a 
median time to clinically significant response of 5 weeks, compared to a median time to 
clinically significant response of 9 weeks for the remainder of the sample, χ2 (1) = 3.80, p 
= .05 (see Figure 2, Panel A). Patients in the upper 75th percentile of session 1 CCT had a 
median time to clinically significant response of 14 weeks, compared to a median time to 
clinically significant response of 7 weeks for the remainder of the sample. However, the 
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difference between these survival estimates only approached significance, χ2 (1) = 3.5, p 
= .06 (see Figure 2, Panel B). 
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CHAPTER 4 
DISCUSSION 
 
 We tested CT and CCT as predictors of (a) change in worry across acute 
treatment, (b) hazard of clinically significant response, and (c) treatment efficiency, or 
time to clinically significant response, across both standard CBT and integrative MI-CBT 
for GAD. Regarding the relation between patient motivational language and worry level 
and change, CCT associated with a slower rate of worry reduction at midtreatment across 
both treatments. With regard to CT, CBT patients with higher vs. lower CT had less 
worry and a faster rate of worry reduction, whereas for MI-CBT patients, CT was 
unrelated to the worry outcomes. Regarding the relation between patient motivational 
language and clinically significant response, across both treatments, more CT associated 
with a greater hazard of response, and more CCT associated with a lower hazard of 
response (with each variable predicting efficiency of response in a consistent manner, but 
at a trend level). 
 Our results generally replicate previous research patterns that link CT and CCT, 
especially when observed through language, with positive and negative outcomes, 
respectively (e.g., Moyers et al., 2007; Magill et al., 2014; Poulin et al., 2018). They 
extend prior research by showing that these associations largely hold for the more 
proximal outcomes vs. distal, posttreatment outcomes only, and whether receiving 
standard CBT or integrative MI-CBT for GAD. In this sense, patients engaging in more 
CT is a common facilitating factor, whereas engaging in more CCT is a common 
hindering factor, both of which can be informative for case conceptualization and 
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treatment planning. Thus, our results continue to highlight the importance of patient 
motivational language as a clinical prognosticator of varied forms of dimensional and 
categorical treatment response; that is, the likelihood that standard or adapted CBT will 
work for a given patient with GAD (with regard to dimensional symptom reduction or 
crossing a clinical significance threshold), and how long it might be expected to take 
before showing its ameliorative effect. 
 Regarding the latter outcome, it might be useful for clinicians to use motivational 
language (of both types) as an important input into estimations of treatment dose. As the 
present data suggest that higher CT and lower CCT will require fewer sessions for 
response, whereas lower CT and higher CCT will require more sessions (though not an 
inordinately higher number), therapists can use this information to educate their patients 
on expected time course at treatment’s outset. Such education has been shown to change 
patients’ duration expectations and to reduce dropout and facilitate treatment engagement 
(Swift & Callahan, 2011). Of course, this implication should be considered with caution 
given that CT and CCT related only marginally to treatment efficiency. Future research is 
needed to confirm or disconfirm the relevance of these variables for time to response, and 
to test directly associations among motivational language, treatment expectancies, 
treatment processes, and treatment outcomes. 
 Of additional note in the present study is that treatment condition moderated the 
association between CT and dimensional worry level and change and midtreatment. 
Given that CT related to these outcomes in CBT, but not MI-CBT, we can draw on the 
stages of change literature to frame these differential results. Namely, Prochaska, 
Norcross, and DiClemente’s (2013) transtheoretical model emphasizes the importance of 
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matching appropriate therapy modalities to the patient’s readiness to change. In this case, 
highly motivated patients who are in, for example, the preparation stage may derive less 
benefit from therapies using MI spirit and strategy to address the resistance to, or low 
motivation for, change that would be hallmarks of the earlier readiness stages (e.g., 
precontemplation) for which MI was explicitly developed. Instead, these motivated 
patients, as indicated in their higher change-oriented language, might be prepared to 
benefit immediately from more action-oriented therapies, such as CBT. For those with 
lower CT, CBT might be outpacing their change readiness, thereby by resulting in less 
improvement over acute treatment. 
In MI-CBT, it is possible that MI levels the playing field, so to speak, for those 
with lower vs. higher change readiness, as indicated in their CT language. Put differently, 
for patients with lower CT, the integration of MI can help them overcome this risk factor 
given its explicit focus on low intrinsic motivation. However, for patients with higher CT 
(essentially when presenting for treatment), MI might actually interfere with this 
facilitative factor, thereby delaying the benefit that these change-ready patients might 
receive from change-oriented interventions. In these ways, MI might mitigate the 
negative effect of low motivation, but also dampen the positive effect of high motivation, 
essentially negating the influence of language on proximal outcomes.  
Thus, our moderator results may have implications for treatment assignment, at 
least in the context of standard CBT or integrative MI-CBT for GAD. When a patient is 
assessed as engaged in high CT as early session 1, CBT may be the most indicated 
intervention. For patients exhibiting low CT in session 1, MI-CBT may be the most 
indicated. Of course, when patients exhibit high CCT, therapists doing either treatment 
23 
 
will need to attend to this risk factor for poor proximal outcomes. Future work is needed 
to identify the best strategies for doing so, as it may be somewhat surprising that using 
MI integratively did not mitigate such risk. Additionally, future work is also needed to 
replicate our findings with regard to the CT by treatment interaction, as this moderation 
effect emerged for only one of our outcome variables (i.e., dimensional worry change).  
 This study had several limitations. First, although it intentionally investigated CT 
and CCT as independent predictors of proximal treatment response, these language 
variables do not exist in a vacuum. In fact, most patients, across any sample or type of 
clinical population, would likely make both CT and CCT statements. Thus, future 
research should examine the interaction of these variables in order to tease apart how 
their variance combinations may influence treatment outcomes. For example, it is 
possible that a combination of both high CT and high CCT may reflect change 
ambivalence, which is another construct that has been associated with treatment 
resistance, and that could have implications for treatment response.  
Second, treatment response in our survival models was treated as a finite vs. a 
repeated event. This way of measuring response could overlook nuance in that a patient 
could achieve clinically significant response at one point in therapy, but then return to a 
level of symptom severity above the response criterion at another point, and perhaps even 
dip back below it at yet another time, etc. Third, although our study framed patient 
motivational language essentially as a presenting patient trait, future research should look 
beyond the single early time point to better understand language as a state (and how 
change in motivational language relates to both proximal and distal treatment outcomes 
in treatments for GAD). Finally, the generalizability of our findings is limited by our 
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sample of mostly white women with severe worry. Future research should investigate 
whether these patient language-outcome relations hold in other GAD treatment samples 
of differing demographic characteristics and of lesser worry severity. 
 Limitations notwithstanding, the present study adds to the limited research on the 
patient motivational language-outcome association in the treatment of anxiety disorders. 
The results point to potential clinical implications of CT and CCT, especially as they 
relate to treatment selection and prognostication of the proximal outcomes that 
complement posttreatment symptom reduction and functional improvement. With 
additional research that extend to patients with different diagnoses who are receiving 
therapy modalities beyond MI and CBT, it can be determined if patient motivational 
language reaches the level of a transdiagnostic and pantheoretical clinical prognosticator. 
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APPENDIX A 
 
TABLES 
 
Table 1 
 
Participant Characteristics at Baseline by Treatment Condition 
 
 
Note. M = mean; SD = standard deviation; PSWQ = Penn State Worry Questionnaire; CQ 
= Change Questionnaire. 
 CBT (n = 43) MI-CBT (n = 42) 
Variables M SD N % M SD n % 
Age 34.19 11.92   32.45 10.54   
Sex*  
     Female 
     Male 
   
41 
2 
 
95.34 
4.65 
   
34 
8 
 
80.95 
19.05 
Race 
     Caucasian 
     Asian 
     African Canadian 
     Hispanic 
     Multiracial 
   
32 
5 
0 
2 
3 
 
74.42 
11.62 
0.00 
4.65 
6.98 
 
 
  
31 
6 
2 
1 
2 
 
73.81 
14.29 
4.76 
2.38 
4.76 
Annual household income 
     Less than 25,000 
     25,000-50,000 
     50,000-75,000 
     75,000-100,000 
     100,000 or more 
 
 
  
10 
9 
11 
8 
5 
 
23.26 
20.93 
25.58 
18.60 
11.63 
   
6 
8 
8 
6 
13 
 
14.29 
19.05 
19.05 
14.29 
30.95 
Education 
     High school or less 
     Some college/university 
     Completed college 
     Some graduate school 
   
4 
13 
18 
8 
 
9.30 
30.23 
41.86 
18.60 
   
2 
9 
19 
12 
 
4.76 
21.43 
45.24 
28.57 
Marital statusa 
     Single 
     Cohabiting/married 
   
19 
23 
 
44.19 
54.76 
   
18 
24 
 
42.86 
57.14 
Current medication use* 
     Yes 
     No 
Previous psychotherapy 
     Yes 
     No 
Comorbidityb  
     Anxiety disorder 
     Depression/dysthymia 
   
14 
29 
 
32 
11 
 
31 
17 
 
32.56 
67.44 
 
74.42 
25.58 
 
72.09 
39.53 
   
6 
36 
 
31 
11 
 
29 
13 
 
14.29 
85.71 
 
73.81 
26.19 
 
69.05 
30.95 
Outcome variable 
     PSWQ 
 
75.05 
 
3.43 
 
 
  
74.69 
 
3.44 
  
     CQ* 107.23 8.76   101.60 11.50   
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a Category sums to less than 43 (and less than 100%) for the CBT condition due to 
missing data. 
b Category sums to more than each group’s sample size due to some patients having more 
than one comorbid disorder. 
* Groups differences on these variables at baseline were either significant or approached 
significance (p  .05). 
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Table 2 
 
Change-Talk as a Predictor of Midtreatment worry, Subsequent Worry Change, and Subsequent 
Acceleration/Deceleration in the Rate of Worry Change 
                                                                                                                                 
 Unconditional model   CT only model                   CT x Tx model  
Fixed Effects Coefficient (SE) p Coefficient (SE) p Coefficient (SE) p 
Midtreatment PSWQ (intercept), γ00  2.15 (1.21) .079 2.19 (1.18) .066 1.87 (1.15) .108 
     Treatment group, γ01 -- -- -0.77 (2.37) .746 -0.65 (2.30) .778 
     Change-talk session 1, γ02 -- -- -22.10 (10.03) .030 -30.03 (10.37) .005 
     Change-talk x treatment, γ03 -- -- -- -- 47.33 (20.73) .025 
Midtreatment change in PSWQ (slope), γ10  -1.67 (0.15) < .001 -1.66 (0.14) < .001 -1.70 (0.14) < .001 
     Treatment group, γ11 -- -- 0.05 (0.29) .874 0.06 (0.28) .818 
     Change-talk session 1, γ12 -- -- -2.32 (1.22) .060 -3.21 (1.25) .012 
     Change talk x treatment, γ13 -- -- -- -- 5.47 (2.50) .032 
Rate of acceleration/deceleration in PSWQ 
(curvature), γ20 
0.01 (0.2) .651 0.01 (0.02) .682 0.01 (0.02) .596 
     Treatment group, γ21 -- -- 0.01 (0.04) .879 0.01 (0.04) .880 
     Change-talk session 1, γ22 -- -- 0.20 (0.15) .181 0.26 (0.16) .113 
   Change-talk x treatment, γ23 -- -- -- -- 
 
-- -- --       -0.29 (.32) .362 
Random effects  
Variance 
component 
p 
Variance 
component 
p 
Variance 
component 
p 
    PSWQ intercept, 00 112.54 < .001 106.28 < .001 99.46 < .001 
    PSWQ slope, 11 1.64 < .001 1.58 < .001 1.48 < .001 
    PSWQ curvature, 22 0.02 < .001 0.02 < .001 0.02 < .001 
    Level 1, σ2  44.06 -- 44.06 -- 44.06 -- 
Model deviance (df) 8606.48(10) -- 8600.48 (16) -- 8594.44 (19) -- 
 
Note. PSWQ = Penn State Worry Questionnaire, CT = session 1 change-talk 
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Table 3 
 
Counter Change-Talk as a Predictor of Midtreatment worry, Subsequent Worry Change, and 
Subsequent Acceleration/Deceleration in the Rate of Worry Change 
                                                                                                                                 
 Unconditional model   CCT only model                   CCT x Tx model  
Fixed Effects Coefficient (SE) p Coefficient (SE) p Coefficient (SE) p 
Midtreatment PSWQ (intercept), γ00  2.15 (1.21) .079 2.16 (1.19) .074 2.10 (1.20) .086 
     Treatment group, γ01 -- -- -0.90 (2.41) .710 -0.85 (2.41) .724 
     Counter change-talk session 1, γ02 -- -- 15.95 (11.57) .172 16.75 (11.71) .157 
     Counter change-talk x treatment, γ03 -- -- -- -- -6.55 (23.43) .780 
Midtreatment change in PSWQ (slope), γ10  -1.67 (0.15) < .001 -1.67 (0.14) < .001 -1.66 (0.14) < .001 
     Treatment group, γ11 -- -- 0.07 (0.29) .796 0.07 (0.28) .803 
     Counter change-talk session 1, γ12 -- -- 2.88 (1.37) .040 2.80 (1.39) .047 
     Counter change talk x treatment, γ13 -- -- -- -- 1.26 (2.77) .651 
Rate of acceleration/deceleration in PSWQ 
(curvature), γ20 
0.01 (0.2) .651 0.007 (0.02) .672 0.010 (0.02) .594 
     Treatment group, γ21 -- -- 0.02 (0.04) .660 0.01 (0.04) .686 
     Counter change-talk session 1, γ22 -- -- 0.13 (0.17) .462 0.10 (0.17) .557 
   Counter change-talk x treatment, γ23 -- -- -- -- 
 
-- -- --              0.24 (0.34) .501 
Random effects  
Variance 
component 
p 
Variance 
component 
p 
Variance 
component 
p 
    PSWQ intercept, 00 112.54 < .001 106.28 < .001 109.01 < .001 
    PSWQ slope, 11 1.64 < .001 1.58 < .001 1.55 < .001 
    PSWQ curvature, 22 0.02 < .001 0.02 < .001 0.02 < .001 
    Level 1, σ2  44.06 -- 44.08 -- 44.09 -- 
Model deviance (df) 8606.48(10) -- 8599.61 (16) -- 85948.81 (19) -- 
 
Note. PSWQ = Penn State Worry Questionnaire, CCT = session 1 counter change-talk 
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Table 4 
 
Randomly Censored Cases Treated as Though Experiencing Event Immediately After 
Censoring 
 
Variable Β SE HR 95%CI(HR) P 
Change-talk session 1 0.03 0.01 1.03 1.01 - 1.05 .007 
Counter change-talk session 1 -0.06 0.02 0.93 0.90 - 0.97 .001 
Treatment group -0.41 0.23 0.66 0.42 - 1.04 .079 
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Table 5 
 
Randomly Censored Cases Treated as Though Experiencing Event at Largest Event 
Time-Point 
 
Variable Β SE HR 95%CI(HR) P 
Change-talk session 1 0.04 0.01 1.04 1.02 - 1.07 .001 
Counter change-talk session 1 -0.04 0.02 0.95 0.92 - 1.00 .047 
Treatment group -0.07 0.27 1.08 0.55 - 1.59 .790 
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Table 6 
 
Final Cox Proportional Hazards Model 
 
Variable β SE HR 95%CI(HR) p 
Change-talk session 1 0.04 0.01 1.04 1.01 - 1.07 .004 
Counter change-talk session 1 -0.13 0.04 0.87 0.81 - 0.95 .001 
Counter change-talk x Time 0.01 0.01 1.01 1.00 - 1.02 .092 
Treatment group -0.54 0.27 0.58 0.34 - 0.99 .470 
Medication status 0.37 0.28 1.45 0.83 - 2.52 .191 
Site -0.20 0.23 0.82 0.52 - 1.29 .395 
Motivation (Change 
Questionnaire) 
0.01 0.01 1.00 0.98 - 1.02 .852 
Change-talk x Treatment -0.04 0.03 0.96 0.91 -1.02 .166 
Counter change-talk x Treatment -0.02 0.04 0.98 0.90 -1.06 .575 
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APPENDIX B 
 
FIGURES 
 
 
 
 
Figure 1. The moderating effect of treatment group on the CT-worry association. In CBT, 
patients 1 standard deviation above the mean of session 1 CT had a greater decrease in 
worry than patients 1 standard deviation below the mean. In the MI-CBT condition, 
different levels of CT had a negligible impact on worry reduction.  
 
Note. PSWQ = Penn State Worry Questionnaire, CT = session 1 change-talk 
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                                               Panel A
 
                                              Panel B 
 
Figure 2. Survival estimates for different levels of CT and CCT. Panel A depicts the 
survival estimates for the upper 75th percentile of CT at session 1 compared to the rest of 
the sample (0 = 75th percentile, 1 = remainder of the sample). Panel B depicts the survival 
estimates for the upper 75th percentile of CCT at session 1 (0 = 75th %, 1 = remainder of 
the sample). 
 
Note. CT = session 1 change-talk; CCT = session 1 counter change-talk. 
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